Decision to list medical devices supplied by Medtronic New Zealand Limited

Hospital devices Decision

We are pleased to announce the approval of a listing agreement for the supply of medical devices to DHBs.

What we’re doing

We are pleased to announce the approval of a listing agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of cardiology equipment and accessories:

  • cardiac heart valves and accessories
  • electrophysiology equipment and consumables, and
  • ICDs, pacemakers and associated products.

In summary this will result in:

  • Medical devices in the above three cardiology categories from Medtronic being listed in Part III of Section H of the Pharmaceutical Schedule from 1 June 2022 under a national agreement that all DHBs may purchase under; and
  • DHBs being able to continue to purchase other suppliers’ brands of cardiac heart valves and accessories, electrophysiology equipment and consumables, and ICDs, pacemakers and associated products as this agreement is not for sole supply.

Who we think will be most interested

  • DHB staff
    • Cardiac Service Managers
    • Cardiac Surgeons
    • Cardiologists
    • Cardiology unit staff
    • Procurement and supply chain personnel
  • Suppliers and wholesalers

Details about this decision

In coordination with Pharmac, New Zealand Health Partnerships (“NZHP”) has previously released Requests for Proposals (“RFPs”) for ranges of medical devices which Pharmac may list on the Pharmaceutical Schedule. Medtronic entered into agreements with NZHP for cardiac heart valves and accessories, electrophysiology equipment and consumables, and ICDs, pacemakers and associated products as a result of the relevant RFP processes.

In September 2020 Pharmac issued a Registration of Interest (“ROI”) for a range of medical devices, including electrophysiology equipment and consumables, considered for listing on the Pharmaceutical Schedule.

In February 2021 Pharmac issued a ROI for cardiac heart valves and accessories considered for listing on the Pharmaceutical Schedule.

In March 2021 Pharmac issued a ROI for ICDs, pacemakers and associated products considered for listing on the Pharmaceutical Schedule(external link).

As there were not material changes made to the terms and conditions that are currently in place Pharmac decided that consultation on the provisional agreement was not required, and Pharmac has decided to list Medtronic’s cardiac heart valves and accessories, electrophysiology equipment and consumables, and ICDs, pacemakers and associated products in Part III of Section H of the Pharmaceutical Schedule from 1 June 2022.

The list of products will be available on Pharmac's website from 1 June 2022 in both PDF and Excel formats.

DHBs can continue to choose which cardiac heart valves and accessories, electrophysiology equipment and consumables, and ICDs, pacemakers and associated products they procure, include those from other suppliers. DHBs that procure these medical devices from Medtronic must do so under the terms and conditions, including pricing, in the agreement from 1 June 2022.

The agreement includes terms and conditions for training and education to be provided by Medtronic on the appropriate use of its products, which is to be provided at times and in formats as agreed with individual DHBs.

This is the final agreement within the cardiac heart valves and accessories category to result from this ROI process.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.